THE US Food and Drug
Administration is recommending
the re-classification of Vicodin
and other hydrocodone-containing
products from the Drug
Enforcement Administration’s
(DEA) Schedule III list of controlled
substances to the more restrictive
Schedule II list.
B. Douglas Hoey, ceo of the USA’s
National Community Pharmacists
Association said, “This will likely
pose significant hardships and delay
relief for many patients.”
Nursing home and long-term care
patients are to be most affected.The above article was sent to subscribers in Pharmacy Daily's issue from 22 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Nov 13
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.